October 26, 2006 | Atlanta – The Advisory Committee on Immunization Practices (ACIP), a federal panel of immunization experts, has recommended people age 60 and older receive a new vaccine to prevent herpes zoster, or shingles, a condition that often leads to debilitating chronic pain.
The ACIP to the Centers for Disease Control and Prevention (CDC) voted Wednesday, October 25, 2006, to recommend a newly licensed zoster vaccine, Zostavax manufactured by Merck, to protect against shingles be given to all people age 60 and older, including those who have had a previous episode of shingles.
Leave a comment